Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics, Inc. (Nasdaq:ADMA) has announced a public offering of 20,979,020 shares of its common stock at $2.86 per share, aiming for gross proceeds of approximately $60 million. The offering is expected to close on December 9, 2022, with a 30-day option for underwriters to purchase an additional 3,146,853 shares. Proceeds will support commercialization, production activities, plasma center buildout, and FDA approvals. Raymond James, Cantor Fitzgerald, and Mizuho Securities are managing the offering.
ADMA Biologics announced plans for an underwritten public offering of common stock, with underwriters receiving a 30-day option to purchase up to 15% more shares. The offering is contingent on market conditions and the exact size is yet to be determined. Proceeds will be allocated towards commercialization, plasma center expansion, FDA approvals, R&D, and working capital. This follows the company's strategic focus on developing specialty plasma-derived biologics. The offering will be filed under a previously effective registration statement with the SEC.
ADMA Biologics has announced preliminary estimates for its total revenue for Q4 and the full year of 2022. The company expects revenues for Q4 to be between $48 million and $50 million, representing over 85% year-over-year growth from $26.4 million in Q4 2021. For the entire year, projected revenues range from $152 million to $154 million. ADMA specializes in manufacturing and marketing plasma-derived biologics treating immunodeficient patients, further solidifying its position in the biopharmaceutical sector.
ADMA Biologics reported a 99% year-over-year revenue increase for Q3 2022, totaling $41.1 million, with gross profit rising to $9.7 million. The company has raised its FY 2022 revenue guidance to $145 million from $130 million. Gross margins are expected to improve as legacy lower-margin BIVIGAM inventory is exhausted. Operational losses narrowed to $14.9 million, down from $17.7 million in 2021. ADMA anticipates achieving profitability by early 2024, with long-term revenue targets set at approximately $250 million in 2024 and $300 million thereafter.
ADMA Biologics (Nasdaq: ADMA) announced it will release its financial results for Q3 2022 on November 9, 2022, after market close. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics for immunocompromised patients. It currently offers three FDA-approved products including ASCENIV™ and BIVIGAM® for primary immunodeficiency. The company operates a licensed facility in Boca Raton, Florida, and is committed to supporting niche patient populations.
ADMA Biologics announced FDA approval for its seventh plasma collection facility in Greensboro, North Carolina, enhancing its plasma supply self-sufficiency and revenue growth. This new facility, operational since Q1 2022, now complies with FDA standards for human source plasma collection. ADMA aims to achieve ten FDA-licensed plasma centers by the end of 2023, with this being the fourth approval this year. The facility features advanced technology to improve donor experience and is expected to employ 50 trained healthcare professionals.
ADMA Biologics reported strong second quarter 2022 results with total revenues of $33.9 million, a 90% year-over-year increase. Gross profit surged to $7.8 million, marking a 112% improvement from the previous quarter. The company narrowed net losses to $13.8 million, a 45% reduction from the first quarter. Full-year revenue guidance is set to exceed $130 million. Strategic expansions are ongoing, including plans for more FDA-licensed BioCenters. The company also anticipates achieving profitability by Q1 2024 with long-term revenue targets of up to $300 million.
ADMA Biologics, Inc. (Nasdaq: ADMA) will report its Q2 financial results for the period ended June 30, 2022, on August 10, 2022. The announcement includes a live conference call at 4:30 p.m. ET to discuss financial outcomes and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics, currently offering FDA-approved products for immunodeficient patients. The company operates a plasma fractionation facility in Boca Raton, Florida, and also runs FDA-approved plasma collection centers.
ADMA Biologics (Nasdaq: ADMA) announced its inclusion in the Russell 2000® Index, effective June 27, 2022, as per the preliminary list from FTSE Russell released on June 17, 2022. The Russell 2000® Index assesses the performance of small-cap stocks in the U.S. equity market and is a benchmark for numerous investment strategies, managing approximately $12 trillion in assets. ADMA specializes in plasma-derived biologics aimed at treating immunodeficient patients and has three FDA-approved products, including BIVIGAM® and ASCENIV™.
ADMA Biologics reported first quarter 2022 revenues of $29.1 million, an 81% increase from the previous year. This growth has led the company to increase its full-year revenue guidance to $130 million or more. The gross margin improved to 13%, despite a $6.7 million one-time charge due to debt refinancing. ADMA expects continued operational efficiency and profitability, aiming for $250 million in revenue by 2024 and potential margins of 40-50%. The company ended Q1 with $70 million in cash and plans to draw an additional $25 million in non-dilutive funds.